Literature DB >> 24478060

Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis.

David F Ackart1, Laurel Hascall-Dove, Silvia M Caceres, Natalie M Kirk, Brendan K Podell, Christian Melander, Ian M Orme, Jeff G Leid, Jerry A Nick, Randall J Basaraba.   

Abstract

There is an urgent need to improve methods used to screen antituberculosis drugs. An in vitro assay was developed to test drug treatment strategies that specifically target drug-tolerant Mycobacterium tuberculosis. The H37Rv strain of M. tuberculosis survived antimicrobial treatment as attached microbial communities when maintained in tissue culture media (RPMI-1640) with or without lysed human peripheral blood leukocytes. When cultured planktonically in the presence of Tween-80, bacilli failed to form microbial communities or reach logarithmic phase growth yet remained highly susceptible to antimicrobial drugs. In the absence of Tween, bacilli tolerated drug therapy by forming complex microbial communities attached to untreated well surfaces or to the extracellular matrix derived from lysed human leukocytes. Treatment of microbial communities with DNase I or Tween effectively dispersed bacilli and restored drug susceptibility. These data demonstrate that in vitro expression of drug tolerance by M. tuberculosis is linked to the establishment of attached microbial communities and that dispersion of bacilli targeting the extracellular matrix including DNA restores drug susceptibility. Modifications of this in vitro assay may prove beneficial in a high-throughput platform to screen new antituberculosis drugs especially those that target drug-tolerant bacilli.
© 2014 Federation of European Microbiological Societies. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  Mycobacterium tuberculosis; biofilm; drug resistant; drug tolerant; microbial communities

Mesh:

Substances:

Year:  2014        PMID: 24478060      PMCID: PMC4361083          DOI: 10.1111/2049-632X.12144

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  69 in total

Review 1.  Neutrophil extracellular traps: casting the NET over pathogenesis.

Authors:  Florian Wartha; Katharina Beiter; Staffan Normark; Birgitta Henriques-Normark
Journal:  Curr Opin Microbiol       Date:  2007-01-08       Impact factor: 7.934

Review 2.  New insights into the function of granulomas in human tuberculosis.

Authors:  Timo Ulrichs; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

3.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation.

Authors:  E M Bakker; S Volpi; E Salonini; E C van der Wiel-Kooij; C J J C M Sintnicolaas; W C J Hop; B M Assael; P J F M Merkus; H A W M Tiddens
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

5.  Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.

Authors:  L J Piddock; K J Williams; V Ricci
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

6.  Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans.

Authors:  N Ramasubbu; L M Thomas; C Ragunath; J B Kaplan
Journal:  J Mol Biol       Date:  2005-04-14       Impact factor: 5.469

7.  Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2.

Authors:  Sabri B Erdemli; Radhika Gupta; William R Bishai; Gyanu Lamichhane; L Mario Amzel; Mario A Bianchet
Journal:  Structure       Date:  2012-10-25       Impact factor: 5.006

8.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 9.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

10.  Detection of Mycobacterium tuberculosis in serum samples using the polymerase chain reaction.

Authors:  M van Staden; E van der Ryst; E M Attwood; M L Hendricks; G Joubert; D J Weich
Journal:  J Infect       Date:  1998-05       Impact factor: 6.072

View more
  30 in total

Review 1.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

2.  Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold.

Authors:  T Vu Nguyen; Bradley M Minrovic; Roberta J Melander; Christian Melander
Journal:  ChemMedChem       Date:  2019-03-21       Impact factor: 3.466

3.  Second-Generation Meridianin Analogues Inhibit the Formation of Mycobacterium smegmatis Biofilms and Sensitize Polymyxin-Resistant Gram-Negative Bacteria to Colistin.

Authors:  Michael J Zeiler; Roberta J Melander; Christian Melander
Journal:  ChemMedChem       Date:  2020-08-03       Impact factor: 3.466

4.  Analogue synthesis reveals decoupling of antibiofilm and β-lactam potentiation activities of a lead 2-aminoimidazole adjuvant against Mycobacterium smegmatis.

Authors:  Sara E Martin; Catherine M Nguyen; Randall J Basaraba; Christian Melander
Journal:  Chem Biol Drug Des       Date:  2018-05-12       Impact factor: 2.817

Review 5.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

6.  Retention of EsxA in the Capsule-Like Layer of Mycobacterium tuberculosis Is Associated with Cytotoxicity and Is Counteracted by Lung Surfactant.

Authors:  Johanna Raffetseder; Nino Iakobachvili; Vesa Loitto; Peter J Peters; Maria Lerm
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

7.  Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.

Authors:  Yu-Min Chuang; Noton K Dutta; Chien-Fu Hung; T-C Wu; Harvey Rubin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules.

Authors:  David F Ackart; Erick A Lindsey; Brendan K Podell; Roberta J Melander; Randall J Basaraba; Christian Melander
Journal:  Pathog Dis       Date:  2014-02-24       Impact factor: 3.166

Review 9.  Heterogeneous Host-Pathogen Encounters Coordinate Antibiotic Resilience in Mycobacterium tuberculosis.

Authors:  Richa Mishra; Vikas Yadav; Madhura Guha; Amit Singh
Journal:  Trends Microbiol       Date:  2020-12-10       Impact factor: 17.079

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.